Insider Selling: Calidi Biotherapeutics, Inc. (NYSE:CLDI) CEO Sells 10,000 Shares of Stock

Calidi Biotherapeutics, Inc. (NYSE:CLDI) CEO Allan Camaisa sold 10,000 shares of the business’s stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $1.62, for a total value of $16,200.00. Following the transaction, the chief executive officer now directly owns 66,712 shares in the company, valued at $108,073.44. This trade represents a 13.04 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Calidi Biotherapeutics Price Performance

Calidi Biotherapeutics stock traded down $0.29 during midday trading on Wednesday, reaching $1.44. 720,608 shares of the stock traded hands, compared to its average volume of 507,528. Calidi Biotherapeutics, Inc. has a 12-month low of $0.73 and a 12-month high of $19.70. The business has a 50-day simple moving average of $1.68.

Calidi Biotherapeutics (NYSE:CLDI) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.20. Equities research analysts anticipate that Calidi Biotherapeutics, Inc. will post -4.48 earnings per share for the current year.

Institutional Investors Weigh In On Calidi Biotherapeutics

A hedge fund recently raised its stake in Calidi Biotherapeutics stock. Delta Investment Management LLC boosted its stake in Calidi Biotherapeutics, Inc. (NYSE:CLDI) by 1,955.0% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 210,230 shares of the company’s stock after buying an additional 200,000 shares during the quarter. Delta Investment Management LLC owned approximately 0.41% of Calidi Biotherapeutics worth $42,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 12.53% of the company’s stock.

About Calidi Biotherapeutics

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.